Clinical trials: HCV Infection
HCV
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve children weighing between 14 and 35 kg with…
- Trial name
- NCT05854511
- Testing
- Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
HCV Infection
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of oral MK-5172 (a fixed dose combination [FDC] tablet containing elbasvir [EBR] 50 mg and grazoprevir [GZR] 100 mg) and EBR/GZR (varying…
- Trial name
- NCT03379506
- Testing
- EBR/GZR FDC Tablet, Grazoprevir Oral Granules, Elbasvir Oral Granules
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Opioid Use Disorder, HIV Infections
Buprenorphine Integration Research and Community Health
The goal of this clinical trial is to evaluate an intervention strategy in introducing screen/evaluate/treat (SET) procedures for HIV/ hepatitis C/ and Opioid Use Disorder in Primary Care Clinics in West Virginia.
- Conditions
- Opioid Use Disorder, HIV Infections, Hepatitis C
- Trial name
- BIRCH (NCT05668780)
- Testing
- NIATx Coaching
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic, Hepatitis C
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PegIntron plus Rebetol combination therapy administered to patients with chronic hepatitis C.
- Trial name
- NCT00724230
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 505 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Tuberculosis Infection
European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol
Across Europe and worldwide, there are many studies following groups (cohorts) of children living with human immunodeficiency virus (HIV) and other infections over time, to monitor their long-term health.
- Conditions
- HIV Infections, Tuberculosis Infection, Hepatitis C, Covid19
- Trial name
- EPPICC (NCT04677842)
- Testing
- ART Therapy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- PENTA Foundation
Chronic Hepatitis c
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients
The hepatitis C virus is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma, and infects approximately 3 % of the world population (150-170 million).
- Trial name
- NCT03687229
- Testing
- A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR), A)fasting serum glucose, B)Fasting serum insulin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hepatitis C Virus Infection
Screening, Treatment, and Eradication of Hep C
The aim of this study is to assess the HCV screening rate in Arizona by identification of potential HCV patients/subjects through different methods of communication - text message, email, social media, radio, newspaper ads, and…
- Trial name
- NCT05071261
- Testing
- Hepatitis C Virus Screening
- Volunteers
- 112,136 people, healthy volunteers welcome
- Sponsor
- Liver Institute PLLC
HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
Combating Related Epidemics in HCV
This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm).
- Conditions
- HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)
- Trial name
- CREST (NCT07560046)
- Testing
- Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2
- Volunteers
- 1,280 people
- Sponsor
- Duke University
HCV Infection, Beta Thalassemia Major
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of sofosbuvir, ledipasvir and sofosbuvir metabolite (GS-331007) in HCV infected children with hematological Disorders.
- Trial name
- NCT04353986
- Testing
- Sofosbuvir and Ledipasvir
- Where
- Egypt
- Volunteers
- 24 people
- Sponsor
- Ain Shams University
Hepatitis, Viral, Human, Blood Transfusion
Risk of Post Transfusion Hepatitis C Virus Infection
To determine the risk of transfusion-transmitted hepatitis C virus (HCV) in cardiac surgery patients before and after donor screening for anti-HCV and surrogate markers of non-A, non-B hepatitis (NANBH).
- Conditions
- Hepatitis, Viral, Human, Blood Transfusion, Blood Donors
- Trial name
- NCT00005339
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatitis B, Human Immunodeficiency Virus
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.
- Conditions
- Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
- Trial name
- NCT00782301
- Testing
- maraviroc, etravirine
- Where
- 18 sites in United States, Canada and 1 more
- Sponsor
- ViiV Healthcare
Chronic Hepatitis C, Menopause
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)
The cohort of post-menopausal women represents a group of very-difficult-to-treat patients in whom a more powerful approach is required in order to improve the disappointing response rate.
- Trial name
- MEN_BOC (NCT01457937)
- Testing
- Pegylated Interferon, Ribavirin, Boceprevir
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- University of Modena and Reggio Emilia
Hepatitis C, Infectious Disease
HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment
Hepatitis C infection is a major cause of chronic liver disease and death with approximately 3% of the world's population is infected with hepatitis C virus (HCV).
- Trial name
- NCT03524794
- Where
- United Kingdom
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- University College, London
Hepatitis C
The Effect of Adding Metformin to the Treatment of Hepatitis C
Insulin resistance is known to adversely effect viral response to treatment in hepatitis C patients We are aiming to study the effect of an insulin sensitizer, metformin, in viral response of hepatitis C to treatment with…
- Trial name
- NCT00560690
- Testing
- Metformin, pegylated interferon, Ribavirin
- Where
- Iran
- Volunteers
- 140 people
- Sponsor
- Tehran University of Medical Sciences
HIV Infections, Hepatitis C
Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
The purpose of this study is to look at how 2 different anti-HIV drug treatments affect the liver. The use of anti-HIV drugs like the nucleoside reverse transcriptase inhibitors (NRTIs) may be linked to liver problems like fatty…
- Trial name
- NCT00023218
- Testing
- Lopinavir/Ritonavir, Efavirenz
- Where
- 3 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
History of Hepatitis C in Volunteer Blood Donors
Hepatitis C is a disease of the liver caused by the Hepatitis C Virus (HCV). Patients with hepatitis C may feel well and show no signs or symptoms of being ill.
- Trial name
- NCT00001982
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Decompensation, Hepatocellular Carcinoma
The Second Multicenter Hemophilia Cohort Study
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV).
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT00341705
- Where
- 48 sites in United States, Brazil and 6 more
- Volunteers
- 2,565 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C, Chronic
Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV
Egypt has the highest prevalence of hepatitis C virus infection in adults (up to 20%) and children (up to 5.5%). The major genotype (90%) is type 4.
- Trial name
- NCT02027493
- Testing
- Reiferon R, Ribavirin
- Where
- 3 sites in Egypt
- Volunteers
- 46 people
- Sponsor
- National Liver Institute, Egypt
Hepatitis D, Hepatitis C
Evaluation of Patients With Liver Disease
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.
- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Trial name
- NCT00001971
- Where
- United States
- Volunteers
- 8,050 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)